Condition: Fludzoparib" and Anti-angiogenic · HRD-positive/HER2-negative Advanced Breast Cancer · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
This study develops a new therapeutic approach for HER2-negative advanced breast cancer patients without precise treatment targets. The trial aims at extending the combination target therapy involving PARP inhibitors and anti-angiogenesis from only BRCA mutation carriers to all patients with homologous recombination repair defects (HRD-positive). The phase III randomized clinical study will investigate the effectiveness of the combination therapy of PARP inhibitor "fludzoparib" and anti-angiogenic "apatinib" in treating HRD-positive/HER2-negative advanced breast cancers.
This description comes directly from the study's public registry record.
Zhao Jianli · 86-20-34070870 · zhaojli5@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Sun Yat Sen Memorial Hospital，Sun Yat sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06255392